Clinical Trials
113 trialsDurvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
University of Cincinnati
Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma
University of Wisconsin, Madison
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
OHSU Knight Cancer Institute
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
M.D. Anderson Cancer Center
Safety, Tolerability, and Preliminary Antitumor Activity of Non-Cationic Peptide-CD47 siRNA in Advanced Solid Tumors
West China Hospital
MRG003
Sun Yat-sen University
Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
Fred Hutchinson Cancer Center
Cyclophosphamide and Etoposide as a Metronomic Therapy in Advanced Head and Neck Squamous Cell Cancer
National Cancer Institute, Egypt
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
M.D. Anderson Cancer Center
New MRI Biomarkers in Head and Neck Cancers
Memorial Sloan Kettering Cancer Center
WOLF
University of Pittsburgh
STRAP
National Cancer Centre, Singapore
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors
Mayo Clinic
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
PNeoVCA
Mayo Clinic
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
Rutgers, The State University of New Jersey
Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
University of California, San Diego
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
University of California, San Diego
TAGNOT
Kidney Cancer Research Bureau
A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes
University Health Network, Toronto
MASST
University Health Network, Toronto
Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy
University of Pittsburgh
Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
M.D. Anderson Cancer Center
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC
University of Chicago
Can Recurrence of Cancer in the Oropharynx be Detected by Blood Samples?
Rigshospitalet, Denmark
Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer
University of California, San Diego
Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
Sun Yat-sen University
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors
University of California, San Diego
9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
Dana-Farber Cancer Institute
The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors
Cedars-Sinai Medical Center
Pretreatment With HCQ Before Radiotherapy and Chemotherapy in Advanced NPC Patients
Affiliated Hospital of Nantong University
Reconstruction of Cervical Lymphatic System During Head and Neck Squamous Cell Carcinoma Surgery
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC
Sun Yat-sen University
PembroMetaRT
UNICANCER
Combined Anti-IL6R and Anticoagulation Therapy in Advanced NPC Patients
Affiliated Hospital of Nantong University
Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients
Cedars-Sinai Medical Center
Bintrafusp Alfa in Previously Treated Patients With R/M Non-keratinizing NPC
The University of Hong Kong
A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors
Zhejiang University
Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies
University of California, San Francisco
Non-invasive Measurement of PD-L1 Levels With Positron Emission Tomography (PET) in Head and Neck Malignancies and Intracranial Metastases
Yale University
SUPPRESS
Centre hospitalier de l'Université de Montréal (CHUM)
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
Rutgers, The State University of New Jersey
V-CHANCE
National Cancer Institute, Naples
Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN
Eye & ENT Hospital of Fudan University
Parsabiv-MBD
Columbia University
PD-1 Inhibitors Plus Chemoradiotherapy for Metastatic Nasopharyngeal Carcinoma: an Open-label Single-arm, Phase II Trial
Sichuan Cancer Hospital and Research Institute
Time to Treatment and Disease-free Survival of Patients With High-risk Head-neck Cutaneous Squamous Cell Carcinoma
Maastricht University Medical Center